Neuro-Oncology News

The FDA granted orphan drug designation to silmitasertib for treatment of medulloblastoma.

Surgeons at Lenox Hill Hospital are recruiting patients for a first-in-human, single arm, open-label phase 1 clinical trial investigating the safety and feasibility of using belly fat to treat recurrent glioblastoma.

Severe auditory dysfunction was a common neurobiological feature of neurofibromatosis type 1, according to results of a case-control study published in JAMA Network Open.

A personalized cancer vaccine conferred a PFS benefit to a subset of patients with newly diagnosed glioblastoma, according to phase 2 study results presented at Society for the Immunotherapy of Cancer Annual Meeting.

John F. de Groot, MD, has been appointed chief of the neuro-oncology division at University of California, San Francisco.

In a company release, Accuray Inc. announced its CyberKnife radiotherapy platform, which delivers stereotactic radiosurgery to treat lesions in the brain, was supported by more than 2 decades of globally driven clinical data.

Researchers reported common causes of death and end-of-life care experiences among patients with intracranial high-grade gliomas in a retrospective observational study published in Neurology.

Results of early clinical trials suggest that chimeric antigen receptor T cells can be adapted successfully to target brain tumors, according to a presenter at AACR Virtual Special Conference: Brain Cancer.

Patients with isocitrate dehydrogenase wild-type glioblastoma who used levetiracetam for the duration of chemoradiation may have a higher overall survival rate, according to an observational, retrospective cohort study in Neurology.

In this video from the Annual Meeting of the American Neurological Association, Jennifer Frontera, MD, discussed a plenary session, "Hypoxic/Anoxic Injury in the CNS."